BMS-986504 for Non-Small Cell Lung Cancer

Recruiting in Palo Alto (17 mi)

+21 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Bristol-Myers Squibb

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.

Eligibility Criteria

This trial is for adults over 18 with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) that can't be cured and has worsened after previous treatments. Participants must have a certain type of genetic change in their cancer cells called homozygous MTAP deletion, at least one measurable tumor, and be able to perform daily activities with minimal assistance.

Inclusion Criteria

I am fully active or have some restrictions but can still care for myself.

At least 1 measurable lesion as per RECIST v1.1

My lung cancer is confirmed and lacks MTAP, and I can provide tissue samples.

+4 more

Exclusion Criteria

I have active brain tumors or cancer in the lining of my brain.

I don't have stomach issues that would affect medication absorption.

Known severe hypersensitivity to study treatment and/or any of its excipients

+2 more

Participant Groups

The study tests BMS-986504 as a solo treatment for NSCLC patients who have the specific MTAP deletion. It aims to see how safe it is and how well it works after other treatments have failed. Patients will take this medication orally, meaning they'll swallow tablets whole.

2Treatment groups

Experimental Treatment

Group I: Arm B: BMS-986504 Dose 2Experimental Treatment1 Intervention

Group II: Arm A: BMS-986504 Dose 1Experimental Treatment1 Intervention